These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31573839)

  • 1. Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers.
    Motta G; Vigneri P
    Future Oncol; 2019 Sep; 15(27):3097-3101. PubMed ID: 31573839
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Ackermann CJ; Reck M; Paz-Ares L; Barlesi F; Califano R
    Lung Cancer; 2019 Aug; 134():245-253. PubMed ID: 31319988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.
    Shaikh FY; Gills JJ; Sears CL
    EBioMedicine; 2019 Oct; 48():642-647. PubMed ID: 31597596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
    [No Abstract]   [Full Text] [Related]  

  • 8. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T
    Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
    Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
    Thorac Cancer; 2019 Dec; 10(12):2259-2266. PubMed ID: 31679185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?
    Sukari A; Nagasaka M
    Oral Oncol; 2020 Feb; 101():104435. PubMed ID: 31635973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
    Lara MS; Afify A; Ellis MP; Phan CT; Richman DP; Riess JW
    Clin Lung Cancer; 2019 Jul; 20(4):e489-e491. PubMed ID: 31085042
    [No Abstract]   [Full Text] [Related]  

  • 13. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 15. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression.
    Takeshita M; Anai S; Mishima S; Inoue K
    Ann Oncol; 2017 Jan; 28(1):186-189. PubMed ID: 28043982
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 17. Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy.
    Fontecilla NM; Khanna T; Bayan CY; Antonov NA; Geskin LJ
    J Drugs Dermatol; 2019 Jan; 18(1):103-104. PubMed ID: 30681807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab in advanced non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Aug; 18(8):e434. PubMed ID: 28648559
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
    Tabchi S; Weng X; Blais N
    Lung Cancer; 2016 Sep; 99():123-6. PubMed ID: 27565926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.